• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Gilead Sciences (GILD)

Common Shares
Sell: $64.79|Buy: $64.82|Change: 0.55 (-0.84%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Address

333 Lakeside Drive
Foster
CA
USA
94404

Telephone

+1 650 574-3000

Website

https://www.gilead.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Gilead Sciences Inc Annual General Meeting for 20252025-05-08T10:00:00
Gilead Sciences Inc First Quarter Earnings Conference Call for 20252025-04-25T16:30:00
Gilead Sciences Inc First Quarter Earnings Results for 20252025-04-25T00:00:00
Gilead Sciences Inc Annual Report for 20242025-02-21T00:00:00
Gilead Sciences Inc Fourth Quarter Earnings Conference Call for 20242025-02-06T14:00:00
Gilead Sciences Inc Fourth Quarter Earnings Results for 20242025-02-06T00:00:00
Gilead Sciences Inc Third Quarter Earnings Conference Call for 20242024-11-07T16:30:00
Gilead Sciences Inc Third Quarter Earnings Results for 20242024-11-07T00:00:00
Gilead Sciences Inc Second Quarter Earnings Conference Call for 20242024-08-02T17:00:00
Gilead Sciences Inc Second Quarter Earnings Results for 20242024-08-02T00:00:00
Goldman Sachs Annual Global Healthcare Conference2024-06-12T13:20:00
Jefferies Global Healthcare Conference2024-06-05T11:00:00
RBCCM Global Healthcare Conference2024-05-15T10:30:00
BofA Securities Health Care Conference2024-05-14T11:20:00
Gilead Sciences Inc Annual General Meeting for 20242024-05-08T10:00:00

Previous key dates

NameKey Date
RBCCM Global Healthcare Conference2024-05-15T10:30:00
BofA Securities Health Care Conference2024-05-14T11:20:00
Gilead Sciences Inc Annual General Meeting for 20242024-05-08T10:00:00
Gilead Sciences Inc First Quarter Earnings Conference Call for 20242024-04-25T16:30:00
Gilead Sciences Inc First Quarter Earnings Result for 20242024-04-25T00:00:00
Barclays Annual Global Healthcare Conference2024-03-13T11:15:00
Leerink Partners Global Biopharma Conference2024-03-12T10:00:00
TD Cowen Annual Health Care Conference2024-03-05T12:50:00
Gilead Sciences Inc Annual Report for 20232024-02-23T00:00:00
Gilead Sciences Inc Fourth Quarter Earnings Conference Call for 20232024-02-06T14:00:00
Gilead Sciences Inc Fourth Quarter Earnings Result for 20232024-02-06T00:00:00
Gilead Sciences Inc Third Quarter Earnings Conference Call for 20232023-11-07T16:30:00
Gilead Sciences Inc Third Quarter Earnings Result for 20232023-11-07T00:00:00
Gilead Sciences Inc Second Quarter Earnings Conference Call for 20232023-08-03T17:00:00
Gilead Sciences Inc Second Quarter Earnings Result for 20232023-08-03T00:00:00
Gilead Sciences Inc Annual General Meeting for 20232023-05-03T10:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.